Only the Wnt pathway was significantly enriched following trastuzumab-containing therapy, and this was specifically observed in HER2 + ΔCD36 + BC (Fig. 4A and Supplementary Fig. S16). The gene discussed is ERBB2; the disease is breast cancer.